Cargando…
The anticancer effects of HDAC inhibitors require the immune system
Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFN...
Autores principales: | West, Alison C, Smyth, Mark J, Johnstone, Ricky W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962507/ https://www.ncbi.nlm.nih.gov/pubmed/24701376 http://dx.doi.org/10.4161/onci.27414 |
Ejemplares similares
-
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012) -
Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies
por: Verbrugge, Inge, et al.
Publicado: (2012) -
HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013) -
Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy
por: Ma, Yuting, et al.
Publicado: (2014) -
A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)